RxDoctor Payments Data

Kevin Rist, MD

Clinical Cardiac Electrophysiology · Wausau, WINPI 1497734750

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $10,509 of the $15,650 with a category attached, or 67.1%. Atricure, Inc. accounts for 60.3% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2021 at $8,050 and has fallen 90.8% since, to $739 in 2025.

$15,650in general payments, 2019–2025

Across 93 payments — averaging $168.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Atricure, Inc.$9K
  • Abbott$4K
  • Cardiofocus, Inc.$1K
  • Medtronic$670
  • Boston Scientific$166
  • Abiomed$89
  • plus $578 from 9 others
$185,659in research payments, 2019–2025

Across 68 payments — averaging $2730.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$177K
  • Atricure, Inc.$8K

What the payments were for

  • Travel & lodging$10,50967%
  • Food & beverage$5,14233%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,650 in reported general payments places this provider in the 55th percentile of 78 clinical cardiac electrophysiology providers in Wisconsin.

See all clinical cardiac electrophysiology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$137,221
Medicare patients
1,459
Services billed
2,682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban323$299,463
XareltoRivaroxaban82$88,606
MultaqDronedarone Hcl76$66,351
EntrestoSacubitril/Valsartan27$33,936
JardianceEmpagliflozin41$33,130
CorlanorIvabradine Hcl18$13,069
Metoprolol Succinate447$7,295
Flecainide Acetate125$5,633
Amiodarone Hcl236$5,404
Propafenone Hcl122$4,381
Dofetilide31$3,319
Mexiletine Hcl32$2,605
SotalolSotalol Hcl103$2,307
Dabigatran EtexilateDabigatran Etexilate Mesylate14$2,302
Potassium Chloride63$1,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$64$299,463323 claims
Johnson & JohnsonXarelto$77$88,60682 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 78 clinical cardiac electrophysiology providers in Wisconsin.

Other clinical cardiac electrophysiology in Wausau

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →